Kinetic and structural studies on the interactions of Torpedo californica acetylcholinesterase with two donepezil-like rigid analogues

References

• Hedden T, Gabrieli JDE. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci 2004;5:87–96.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–6.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44–84.
   PubMed Web of Science ®Google Scholar
• Cavadas C, Aveleira CA, Souza GF, et al. The pathophysiology of defective proteostasis in the hypothalamus – from obesity to ageing. Nat Rev Endocrinol 2016;12:723–33.
   PubMed Web of Science ®Google Scholar
• Terry AV, Buccafusco J. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:821–7.
   PubMed Web of Science ®Google Scholar
• Eikelenboom P, Veerhuis R, Scheper W, et al. The significance of neuroinflammation in understanding Alzheimer’s disease. J Neural Transm 2006;113:1685–95.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Schenk D. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545–84.
   PubMed Web of Science ®Google Scholar
• De Ferrari GV, Canales M, Shin I, et al. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001;40:10447–57.
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102:17213–8.
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Bartolini M, Tarozzi A, et al. Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg Med Chem Lett 2011;21:2655–8.
   PubMed Web of Science ®Google Scholar
• Rosini M, Simoni E, Bartolini M, et al. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer’s disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem 2008;51:4381–4.
   PubMed Web of Science ®Google Scholar
• Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012;148:1204–22.
   PubMed Web of Science ®Google Scholar
• Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014;13:759–74.
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3:211–25.
   PubMed Web of Science ®Google Scholar
• Sağlık BN, Ilgın S, Özkay Y. Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes. Eur J Med Chem 2016;124:1026–40.
   PubMed Web of Science ®Google Scholar
• Wang ZM, Cai P, Liu QH, et al. Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem 2016;123:282–97.
   PubMed Web of Science ®Google Scholar
• Chierrito TPC, Pedersoli-Mantoani S, Roca C, et al. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer’s disease. Eur J Med Chem 2017;139:773–91.
   PubMed Web of Science ®Google Scholar
• Lan JS, Zhang T, Liu Y, et al. Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors. Eur J Med Chem 2017;133:184–96.
   PubMed Web of Science ®Google Scholar
• van Greunen DG, Cordier W, Nell M, et al. Targeting Alzheimer’s disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil. Eur J Med Chem 2017;127:671–90.
   PubMed Web of Science ®Google Scholar
• Mishra CB, Kumari S, Manral A, et al. Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem 2017;125:736–50.
   PubMed Web of Science ®Google Scholar
• Peauger L, Azzouz R, Gembus V, et al. Donepezil-based central acetylcholinesterase inhibitors by means of a “Bio-Oxidizable” prodrug strategy: design, synthesis, and in vitro biological evaluation. J Med Chem 2017;60:5909–26.
   PubMed Web of Science ®Google Scholar
• Azzouz R, Peauger L, Gembus V, et al. Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine “bio-oxidizable prodrugs: synthesis, biological evaluation and structure–activity relationship”. Eur J Med Chem 2018;145:165–90.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Z-M, Li X-M, et al. Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer’s disease based on the fusion of donepezil and melatonin. Bioorg Med Chem 2016;24:4324–38.
   PubMed Web of Science ®Google Scholar
• Li F, Wang ZM, Wu JJ, et al. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer’s disease. J Enzyme Inhib Med Chem 2016;31:41–53.
   PubMed Web of Science ®Google Scholar
• Wu MY, Esteban G, Brogi S, et al. Donepezil-like multifunctional agents: design, synthesis, molecular modeling and biological evaluation. Eur J Med Chem 2016;121:864–79.
   PubMed Web of Science ®Google Scholar
• Xie SS, Lan JS, Wang X, et al. Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer’s disease. Bioorg Med Chem 2016;24:1528–39.
   PubMed Web of Science ®Google Scholar
• Prati F, Bergamini C, Fato R, et al. Novel 8-hydroxyquinoline derivatives as multitarget compounds for the treatment of Alzheimer’s disease. ChemMedChem 2016;11:1284–95.
   PubMed Web of Science ®Google Scholar
• Cai P, Fang SQ, Yang XL, et al. Rational design and multibiological profiling of novel donepezil-trolox hybrids against Alzheimer’s disease, with cholinergic, antioxidant, neuroprotective, and cognition enhancing properties. ACS Chem Neurosci 2017;8:2496–511.
   PubMed Web of Science ®Google Scholar
• Dias KS, de Paula CT, Dos Santos T, et al. Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer’s disease. Eur J Med Chem 2017;130:440–57.
   PubMed Web of Science ®Google Scholar
• Prati F, Bottegoni G, Bolognesi ML, et al. BACE-1 inhibitors: from recent single-target molecules to multitarget compounds for Alzheimer’s disease. J Med Chem 2018;61:619–37.
   PubMed Web of Science ®Google Scholar
• Prati F, Cavalli A, Bolognesi ML. Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer’s disease. Molecules 2016;21:466.
   PubMed Web of Science ®Google Scholar
• Rampa A, Mancini F, De Simone A, et al. From AChE to BACE1 inhibitors: the role of the amine on the indanone scaffold. Bioorg Med Chem Lett 2015;25:2804–8.
   PubMed Web of Science ®Google Scholar
• Piazzi L, Rampa A, Bisi A, et al. 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterae and acetylcholinesterase-induced β-amyloid aggregation: a dual function lead for Alzheimer’s disease therapy. J Med Chem 2003;46:2279–82.
   PubMed Web of Science ®Google Scholar
• Piazzi L, Cavalli A, Belluti F, et al. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J Med Chem 2007;50:4250–4.
   PubMed Web of Science ®Google Scholar
• Rizzo S, Bartolini M, Ceccarini L, et al. Targeting Alzheimer’s disease: novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem 2010;18:1749–60.
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Iimura Y, Yamanishi Y, et al. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J Med Chem 1995;38:4821–9.
   PubMed Web of Science ®Google Scholar
• Dubey SK, Kharbanda M, Dubey SK, et al. A new commercially viable synthetic route for donepezil hydrochloride: anti-Alzheimer’s drug. Chem Pharm Bull 2010;58:1157–60.
   PubMed Web of Science ®Google Scholar
• Oliverio M, Nardi M, Costanzo P, et al. Non-conventional methodologies in the synthesis of 1-indanones. Molecules 2014;19:5599–610.
   PubMed Web of Science ®Google Scholar
• Menezes JCJMDS. Arylidene indanone scaffold: medicinal chemistry and structure–activity relationship view. RSC Adv 2017;7:9357–72.
   Web of Science ®Google Scholar
• Costanzo P, Cariati L, Desiderio D, et al. Design, synthesis, and evaluation of Donepezil-like compounds as AChE and BACE-1 inhibitors. ACS Med Chem Lett 2016;7:470–5.
   PubMed Web of Science ®Google Scholar
• Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999;7:297–307.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Sussman JL, Harel M, Frolow F, et al. Purification and crystallization of a dimeric form of acetylcholinesterase from Torpedo californica subsequent to solubilization with phosphatidylinositol-specific phospholipase C. J Mol Biol 1988;203:821–3.
   PubMed Web of Science ®Google Scholar
• Lausi A, Polentarutti M, Onesti S, et al. Status of the crystallography beamlines at Elettra. Eur Phys J plus 2015;130:43.
   Web of Science ®Google Scholar
• Leslie AG. The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr 2006;62:48–57.
   PubMedGoogle Scholar
• Battye TGG, Kontogiannis L, Johnson O, et al. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 2011;67:271–81.
   PubMedGoogle Scholar
• Winn MD, Ballard CC, Cowtan KD, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011;67:235–42.
   PubMed Web of Science ®Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, et al. Phaser crystallographic software. J Appl Crystallogr 2007;40:658–74.
   PubMed Web of Science ®Google Scholar
• Dym O, Song W, Felder C, et al. The impact of crystallization conditions on structure-based drug design: a case study on the methylene blue/acetylcholinesterase complex. Prot Sci 2016;25:1096–114.
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Skubák P, Lebedev AA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 2011;67:355–67.
   PubMed Web of Science ®Google Scholar
• Read RJ. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr 1986;A42:140–9.
   Google Scholar
• Emsley P, Lohkamp B, Scott WG, et al. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr 2010;66:486–501.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem 2009;16:2785–91.
   Web of Science ®Google Scholar
• Iserloh U, Wu Y, Cumming JN, et al. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg Med Chem Lett 2008;18:414–41.
   PubMed Web of Science ®Google Scholar
• Schüttelkopf AW, van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 2004;60:1355–63.
   PubMed Web of Science ®Google Scholar
• Huey R, Garrett MM, Olson AJ, et al. A semiempirical free energy force field with charge-based desolvation. J Comput Chem 2007;28:1145–52.
   PubMed Web of Science ®Google Scholar
• DeLano WL. PyMOL: An open-source molecular graphics tool. CCP4 Newsletter on Protein Crystallography 2002;40:82–92.
   Google Scholar
• Engh RA, Huber R. Structure quality and target parameters. In: Arnold E, Himmel DM, Rossmann MG, eds. International Tables for Crystallography Volume F: Crystallography of biological macromolecules. Chichester: Wiley; 2012:474–84.
   Google Scholar
• Chen VB, Arendall WB, Headd JJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 2010;66:12–21.
   PubMed Web of Science ®Google Scholar
• Kleywegt GJ. Validation of protein models from Cα coordinates alone. J Mol Biol 1997;273:371–6.
   PubMed Web of Science ®Google Scholar
• Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993;90:9031–5.
   PubMed Web of Science ®Google Scholar
• Barate SS, Kumar V, Vishwakarma RA. Determining partition coefficient (Log P), distribution coefficient (Log D) and ionization constant (pKa) in early drug discovery. Comb Chem High Throughput Screen 2016;19:461–9.
   PubMed Web of Science ®Google Scholar
• Gallivan JP, Dougherty D. Cation-π interaction in structural biology. Proc Natl Acad Sci USA 1999;96:9459–64.
   PubMed Web of Science ®Google Scholar
• Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1996;8:127–34.
   Google Scholar
• Raves ML, Harel M, Pang Y-P, et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (−)-huperzine A. Nat Struct Biol 1997;4:57–63.
   PubMedGoogle Scholar
• Koellner G, Kryger G, Millard CB, et al. Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica. J Mol Biol 2000;296:713–35.
   PubMed Web of Science ®Google Scholar
• Saxena A, Fedorko JM, Vinayaka CR, et al. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases. Eur J Biochem 2003;270:4447–58.
   PubMedGoogle Scholar